Company Focus
Daiichi Sankyo
Latest Daiichi Sankyo News
Biotechnology
Japanese drugmaker Daiichi Sankyo is deepening its push into AI-driven oncology, partnering with USA-based Imagene AI to advance biomarker discovery and response prediction across its cancer pipeline. 10 April 2026
Related News
Insights
Company Spotlight
A clinical-stage biopharmaceutical company developing first-in-class programmed off-the-shelf cellular immunotherapies for cancer and autoimmune diseases.
Latest News & Features of interest to Daiichi Sankyo
Pharmaceutical
German pharma Boehringer Ingelheim has handed full commercial and marketing rights for digital schizophrenia therapy CT-155 to US-based Click Therapeutics, reshaping a partnership first struck in 2020. 10 April 2026
Biotechnology
Japanese drugmaker Daiichi Sankyo is deepening its push into AI-driven oncology, partnering with USA-based Imagene AI to advance biomarker discovery and response prediction across its cancer pipeline. 10 April 2026
Pharmaceutical
USA-based neurodegenerative disorders specialist Annovis Bio today revealed that it has secured financing to support the development of its investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s and Parkinson’s. 10 April 2026
Pharmaceutical
Tempus AI , a technology company leading the adoption of AI to advance precision medicine, has announced an expanded, multi-year collaboration with Gilead Sciences aimed at building and advancing Gilead’s oncology pipeline. 10 April 2026
Biotechnology
Swedish immuno-oncology firm Alligator Bioscience saw its shares jump 28.7% to 0.20 kronor this morning, after it provided a brief update regarding its mitazalimab. 10 April 2026
Pharmaceutical
US biotech Avalyn Pharma has filed for a Nasdaq initial public offering, aiming to raise $100 million to fund late-stage development of its inhaled therapies for pulmonary fibrosis. The Boston-based company plans to list under the ticker AVLN, with proceeds focused on advancing two lead candidates. 10 April 2026
Biotechnology
US clinical-stage biotech C4 Therapeutics (C4T) announced that it has entered into a new collaboration agreement with Roche to advance research in the emerging degrader-antibody conjugate (DAC) modality. 10 April 2026
Pharmaceutical
US pharma major AbbVie has filed a lawsuit seeking to narrow the definition of a “340B patient,” opening a new legal front in a long-running dispute over the US drug discount program. 9 April 2026
Pharmaceutical
US biotech Sidewinder Therapeutics has secured $137 million in an oversubscribed series B financing to advance its bispecific antibody-drug conjugate (ADC) pipeline for cancer. 9 April 2026
Pharmaceutical
Japanese pharma major Daiichi Sankyo has entered a collaboration with Shanghai-based ATLATL Innovation Center to source early-stage technologies across Asia-Pacific, sharpening its push into external innovation. 9 April 2026
Latest In Brief for Daiichi Sankyo
Biotechnology
UK biotech Semarion has secured $3.8 million (£2.9 million) to expand manufacturing and commercial reach of its cell-based screening technology, as it moves to convert early pharma interest into broader adoption. 31 March 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze